You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Follow-up Care for Survivors of Lymphoma who have Received Curative-Intent Treatment

ID: 26-5 Apr 2016
Type of Content: Guidelines & Advice, Evidence Summary
Document Status: Current
Authors:
J. Sussman, N. Varela, M. Cheung, L. Hicks, D. Kraftcheck, J. Mandel, G. Fraser, L. Jimenez-Juan, A. Boudreau, S. Sajkowski, R. McQuillan

Guideline Objective

To report the available data regarding the posttreatment follow-up and surveillance of patients with lymphoma treated with curative intent.

Patient Population

All asymptomatic adolescent (≥15 years) and adult survivors of lymphoma who have completed curative-intent treatment and undergo routine follow-up for lymphoma; these patients may or may not be followed by an oncologist.

Intended Guideline Users

All people involved in clinical follow-up of asymptomatic survivors of lymphoma who have received curative-intent treatment including hematologists, medical and radiation oncologists, radiologists, family physicians, nurses, and administrators and policy makers.

Research Question(s)

Three research questions were developed to direct the search for available evidence on the follow-up of asymptomatic survivors of lymphoma who have received curative-intent treatment.

  1. What clinical activities have been shown to be effective at detecting clinical recurrence or further hematological neoplasm?
  2. What is the appropriate frequency and timing for the clinical activities that have been shown to be effective at detecting clinical recurrence or further hematological neoplasm (malignancy)?
  3. What surveillance procedures have been shown to be effective at detecting therapy-related secondary malignancies following treatment for lymphoma?
pdf download Full Report (PDF) (578.13 KB)